Extracellular Vesicles-Based Biomarkers Represent a Promising Liquid Biopsy in Endometrial Cancer
Por favor, use este identificador para citas ou ligazóns a este ítem:
http://hdl.handle.net/10347/23863
Ficheiros no ítem
Metadatos do ítem
Título: | Extracellular Vesicles-Based Biomarkers Represent a Promising Liquid Biopsy in Endometrial Cancer |
Autor/a: | Herrero Filgueira, Carolina Fuente González, Alexandre de la Casas Arozamena, Carlos Sebastián, Víctor Prieto, Martín Arruebo, Manuel Abalo, Alicia Colás, Eva Moreno Bueno, Gema Gil Moreno, Antonio Vilar, Ana Cueva, Juan Abal Posada, Miguel Muinelo Romay, Laura |
Centro/Departamento: | Universidade de Santiago de Compostela. Departamento de Cirurxía e Especialidades Médico-Cirúrxicas |
Palabras chave: | EVs | ExoGAG | Endometrial cancer | ANXA2 | |
Data: | 2019 |
Editor: | MDPI |
Cita bibliográfica: | Herrero, C.; de la Fuente, A.; Casas-Arozamena, C.; Sebastian, V.; Prieto, M.; Arruebo, M.; Abalo, A.; Colás, E.; Moreno-Bueno, G.; Gil-Moreno, A.; Vilar, A.; Cueva, J.; Abal, M.; Muinelo-Romay, L. Extracellular Vesicles-Based Biomarkers Represent a Promising Liquid Biopsy in Endometrial Cancer. Cancers 2019, 11, 2000 |
Resumo: | Tumor-derived extracellular vesicles (EVs) are secreted in large amounts into biological fluids of cancer patients. The analysis of EVs cargoes has been associated with patient´s outcome and response to therapy. However, current technologies for EVs isolation are tedious and low cost-efficient for routine clinical implementation. To explore the clinical value of circulating EVs analysis we attempted a proof-of-concept in endometrial cancer (EC) with ExoGAG, an easy to use and highly efficient new technology to enrich EVs. Technical performance was first evaluated using EVs secreted by Hec1A cells. Then, the clinical value of this strategy was questioned by analyzing the levels of two well-known tissue biomarkers in EC, L1 cell adhesion molecule (L1CAM) and Annexin A2 (ANXA2), in EVs purified from plasma in a cohort of 41 EC patients and 20 healthy controls. The results demonstrated the specific content of ANXA2 in the purified EVs fraction, with an accurate sensitivity and specificity for EC diagnosis. Importantly, high ANXA2 levels in circulating EVs were associated with high risk of recurrence and non-endometrioid histology suggesting a potential value as a prognostic biomarker in EC. These results also confirmed ExoGAG technology as a robust technique for the clinical implementation of circulating EVs analyses |
Versión do editor: | https://doi.org/10.3390/cancers11122000 |
URI: | http://hdl.handle.net/10347/23863 |
DOI: | 10.3390/cancers11122000 |
E-ISSN: | 2072-6694 |
Dereitos: | © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/) Atribución 4.0 Internacional |
Coleccións
-
- EST-Artigos [123]
O ítem ten asociados os seguintes ficheiros de licenza: